Echocardiographic description and outcomes in a heterogeneous cohort of patients undergoing mitral valve surgery with and without mitral annular disjunction: a health service evaluation

Sadie Bennett1*, Jacopo Tafuro1, Marcus Brumpton1, Caragh Bardolia1, Grant Heatlie1, Simon Duckett1,2, Paul Ridley1, Prakash Nanjaiah1 and Chun Shing Kwok1,2

Abstract

Background: Mitral annular disjunction (MAD) is a structural abnormality characterized by the distinct separation of the mitral valve annulus/left atrium wall and myocardium. Little is known about the significance of MAD in patients requiring mitral valve surgery. This evaluation evaluates the echocardiographic characteristics and patient outcomes for patients with and without MAD who require mitral valve surgery.

Methods: All patients who underwent mitral valve surgery and who had a pre-surgical transthoracic echocardiogram between 2013 and 2020 were included. Patient demographics and clinical outcomes were collected on review of patient electronic records.

Results: A total of 185 patients were included in the analysis of which 32.4% had MAD (average MAD length 8.4 mm). MAD was seen most commonly in patients with mitral valve prolapse and myxomatous mitral valves disease (90% and 60% respectively). In the patients with MAD prior to mitral valve surgery, only 3.9% had MAD post mitral valve surgery. There were no significant difference in the severity of post-operative mitral regurgitation, arrhythmic events or major adverse cardiovascular events in patients with and without MAD.

Conclusions: MAD is common in patients who undergo mitral valve surgery. Current surgical techniques are able to correct the MAD abnormality in the vast majority of patients. MAD is not associated with an increased risk of adverse clinical outcomes post mitral valve surgery.

Keywords: Mitral valve surgery, Mitral annular disjunction, Clinical outcomes

Introduction

Mitral annular disjunction (MAD) is a common structural abnormality defined by a distinct separation of the left atrium or mitral valve annulus and myocardium continuum (See Figs. 1 and 2) [1]. MAD is prevalent in patients with mitral valve disease particularly mitral valve prolapse [2]. It is thought to lead to paradoxical annular enlargement and annular flattening in ventricular systole.
which increases the stress placed on the mitral valve apparatus [3]. The hypermobility associated with MAD may also lead to increased left ventricular wall stress which may contribute to myocardial fibrosis, and left ventricular systolic impairment [4].

Mitral valve repair or mitral valve replacement in patients with severe mitral valve disease is associated with good long term patient outcomes [5, 6]. However, less favourable surgical outcomes have been reported in patients who have excessive mobility of the mitral leaflet.
or apparatus [7]. Echocardiography represent an effective method of evaluating MAD and mitral valve disease as this imaging modality has a good balance of temporal and spatial resolution. The lower cost and non-invasive approach of transthoracic echocardiography (TTE) compared to transoesophageal echocardiography makes it ideal to identify these structural abnormalities and monitor its progression. To date there is limited data how TTE can be used to detect MAD in patients who eventually undergo mitral valve surgery.

To understand the potential significance of MAD in this cohort of patients, we conducted a health service evaluation of patients who underwent TTE prior to mitral valve surgery. The aim of this evaluation was two-fold; 1. To assess patient characteristics and the prevalence of MAD undergoing mitral valve surgery. 2. To assess the post surgical outcomes of patients with and without MAD including changes in MAD severity and adverse events of in-hospital complications, arrhythmic events, cardiovascular events and mortality.

**Methods**

This study was performed as part of an approved, registered (registration number: CA30321) and retrospective clinical audit as defined by our institution's clinical audit and research department. Therefore ethical approval and patient consent was not required. The reporting of this study is in accordance with the strengthening the reporting of observational studies in epidemiology (STROBE) criteria [8].

**Study design**

A retrospective observational evaluation was conducted of patients who underwent mitral valve surgery between 2013 and 2020 in the University Hospital of North Midlands cardiothoracic surgery database. Only patients who had a TTE pre surgery that could be reviewed were included.

**Data collection**

The pre-surgical TTE images were reviewed by two experienced sonographers (JT and SB). The presence, location and extent of MAD, left ventricular ejection fraction and the severity of mitral regurgitation were all evaluated. For the patients with follow up TTE, post-surgical images were reviewed for left ventricular ejection fraction, right ventricular systolic function and presence, location and extent of MAD. Where multiple scans had been performed only the most recent scan was considered. MAD was defined as the separation of any distance between the attachment of the left atrial wall/mitral valve annulus and basal left ventricular myocardium at the end of ventricular systole. This was assessed in a 360-degree arc of the mitral valve annulus using the parasternal long axis, apical four, two and three chamber views on TTE. Left ventricular ejection fraction and right ventricular systolic function assessment was undertaken in accordance with national guidelines [9].

Mitral valve surgical procedural data, patient characteristics and patient comorbidities was retrieved from the mitral surgery procedural data was collected from cardiothoracic surgery database. Additional data on patient follow up, major adverse cardiovascular events (MACE) and cardiac arrhythmia outcomes were collected by MB and CB from our electronic patient records system. MACE included stroke, myocardial infarction or death which occurred during the follow-up period. Cardiac arrhythmia outcomes including documented evidence of atrial fibrillation, atrial flutter, ventricular tachycardia (sustained and non-sustained) and ventricular fibrillation.

**Statistical analysis**

Statistical analysis was performed by CSK. The cohort was stratified into patients with and without MAD. Descriptive statistics were presented on patient demographics, comorbidities, aetiology of mitral valve disease, echocardiographic variables, surgical risk, operative variables. At follow-up the presence and severity of post-operative mitral regurgitation, arrhythmic events, major cardiovascular adverse events and mortality were also reported. The t-test and Fisher’s test was used for comparing difference between patients with MAD and no MAD for continuous and categorical variables, respectively.

**Results**

There was a total of 558 patients who underwent mitral valve surgery between 2013 to 2020. In order to identify patients with MAD and those without MAD, we retrieved the TTE data however this was only available for 185 patients. Additional file 1: Table S1 shows the characteristics of the included patient cohort (n = 185) compared to the excluded patient cohort (n = 373). In the excluded patient cohort there were more males (p < 0.001), more mechanical valve replacements (p = 0.005). The duration of inpatient stay was slightly shorter for patients that were included in this evaluation compared to those that were excluded (p = 0.027).

As shown in Table 1, there were no statistical differences in terms of patient characteristics and comorbidities comparing patients with and without MAD. Mitral valve surgical intervention data can be seen in Table 2 with additional mitral valve operative data being shown in Additional file 1: Table S2. Mitral valve operative data specific to patients with MVP or myxomatous mitral valves can be seen in Additional file 1: Table S3. Duration
of operation (285 ± 75 min vs 309 ± 122 min, p = 0.19) and post-operative hospital stay (11.9 ± 11.4 days vs 13.0 ± 10.9 days, p = 0.52) were similar amongst patients with and without MAD. The SCTS log Euroscore was significantly lower in patients with MAD than without MAD (4.5 ± 4.7 vs 7.5 ± 11.2, p = 0.043). Mitral valve surgical interventions included mitral valve repair (60.5%), mechanical (22.0%) and bioprosthetic (20%) mitral valve replacement.

Table 3 shows the TTE data for patients with and without MAD. The most common reason for mitral valve surgery was mitral valve prolapse and myxomatous mitral valve disease with moderate or severe mitral regurgitation. MAD was seen most commonly in patients with mitral valve prolapse (MVP) and myxomatous mitral valve (90% and 60% respectively). MAD was also associated with worse degrees of mitral regurgitation (moderate to severe) in comparison to patients without MAD (85.0% vs 68.0%, p = 0.044). In patients with MAD, the average length was 8.4 ± 3.9 mm. MAD was most commonly seen in the infrolateral left ventricular wall in comparison to other left ventricular regions (76.3% vs 23.7%) and was more commonly seen with posterior MVP in comparison to anterior MVP (85.0% vs 25.0%).

Of the 185 patients included in this evaluation, 89 patients had follow up ≥ 4 years with 42 patients having follow-up ≥ 6 years. TTE follow-up duration for patients with and without MAD was similar (834 ± 790 days vs 680 ± 693 days, p = 0.24). Among the patients with a post-operative TTE data, only 2 patients (3.9%) continued to show MAD post mitral valve surgery. Post-operative mitral regurgitation was seen in similar proportions of patients with and without MAD (46.7% vs 41.6%, p = 0.18). Reassuring, the vast majority of patients had mitral regurgitation that was graded as none or mild in severity (43.3% vs 31.2%, p = 0.32).

Table 2 Mitral valve surgical intervention

| Variable                  | Total (n = 185) | MAD (n = 60) | No MAD (n = 125) | p-value |
|---------------------------|----------------|-------------|-----------------|---------|
| Operation type            |                |             |                 |         |
| Ring                      | 112 (60.5%)    | 41 (68.3%)  | 71 (56.8%)      | 0.15    |
| Biological                | 37 (20.0%)     | 11 (18.3%)  | 26 (20.8%)      | 0.85    |
| Mechanical                | 41 (22.2%)     | 8 (13.3%)   | 33 (26.4%)      | 0.058   |
| Type of ring              |                |             |                 |         |
| Annuloplasty only         | 11 (9.8%)      | 3 (7.3%)    | 8 (11.3%)       | 0.74    |
| Annuloplasty + leaflet repair | 65 (58.0%) | 29 (70.7%)  | 36 (50.7%)      | 0.048   |
| Resection with neochords  | 23 (20.5%)     | 7 (17.1%)   | 16 (22.5%)      | 0.63    |
| Replacement               | 14 (12.5%)     | 2 (4.9%)    | 12 (16.9%)      | 0.079   |
| AF ablation               | 17 (9.2%)      | 7 (11.7%)   | 10 (8.0%)       | 0.68    |
| Left atrial appendage cl/ | 18 (9.7%)      | 7 (11.7%)   | 11 (8.8%)       | 0.81    |
difference in MACE in patients with and without MAD. During the follow-up duration a total of 40 patients died, causes of death can be seen in Additional file 1: Table S4. Survival analysis of patient with and without MAD can be seen in Additional file 1: Fig. S1.

**Discussion**

Our retrospective study highlights that MAD is a common finding in patients requiring mitral valve surgery for any aetiology, with MAD occurring in approximately one third of patients. In this population, it is most common among patients with mitral valve prolapse and myxomatous mitral valve disease. Our results suggest that MAD does not affect surgical outcomes and surgery appears to correct the MAD in a vast majority of patients. In this population, we found no evidence of increased arrhythmic risk for patients with MAD compared to no MAD. These findings suggest that MAD is a frequent incidental finding in patients who undergo mitral valve surgery which does not impact patient outcomes.

We found that MAD is common in patients undergoing mitral valve surgery which has been described before. Eriksson et al. reported a much higher prevalence of MAD of 97% in advanced myxomatous mitral valve disease and 9% in mild to moderate myxomatous mitral valve disease [7]. The difference in rate in Eriksson et al. likely related to the difference in the evaluated population. The current study includes all aetiologies for mitral valve disease requiring surgery rather than advanced myxomatous mitral valve disease alone and the current study used TTE rather than transoesophageal echocardiography. Our study results are more consistent with the 38% rate of >5 mm MAD evaluated by TTE in a cohort of 64 patients with Barlow’s disease undergoing mitral valve surgery reported by Hiemstra et al [5] and the rate of 35% in 89 patients with mitral valve prolapse detected on cardiac magnetic resonance imaging described by Essayagh et al. [10].

To the best of our knowledge only one study by Eriksson et al. [7] has investigated patients with and without MAD pre and post mitral valve surgery. Whilst there were similarities between Eriksson et al. [7] and our evaluation in terms patient gender (66% male vs 72.2% male) and MAD length (10±3 mm vs 8.4±3.9 mm). It is difficult to make further comparisons as Erikson et al [7] only included patients with MVP or Barlow’s disease (32 with mild to moderate disease and 32 with advanced disease) who underwent mitral valve repair. The patient cohort studied in Eriksson et al. [7] were generally young (52±12 years vs 65±13.7 years) and had a lower incidence of requiring coronary artery bypass grafting at the time of mitral valve surgery (4.6% vs 19.8%).

| Variable                           | MAD (n=60) | No MAD (n=125) | p-value |
|------------------------------------|------------|----------------|---------|
| MAD length (mm)                    |            |                |         |
| Average ± SD                       | 8.4±3.9    | 8.4±3.9        |         |
| Median [IQR]                       | 7 [5 to 11]| 7 [5 to 11]    |         |
| MAD location                       |            |                |         |
| Infero-lateral                     | 45 (76.3%) | 38 (70.6%)     | 0.28    |
| Other                              | 14 (23.7%) | 17 (30.4%)     |         |
| LVEF                               |            |                |         |
| Average ± SD                       | 60.1±6.4%  | 59.9±6.5%      | 0.69    |
| LV global impairment               | 5 (8.3%)   | 4 (5.6%)       | 1.00    |
| Any RWMA                           | 0 (0%)     | 0 (0%)         | 1.00    |
| Impaired RV function               | 6 (10.0%)  | 10 (12.0%)     | 0.12    |
| MR severity                        |            |                |         |
| Moderate or severe                 | 51 (85.0%) | 49 (79.0%)     | 0.93    |
| Ischaemic heart disease            | 0 (0%)     | 0 (0%)         | 1.00    |
| Infective endocarditis             | 6 (10.0%)  | 3 (6.4%)       | 0.49    |
| MVP                                | 54 (90.0%) | 50 (79.0%)     | 0.85    |
| Anterior                           | 15 (25.0%) | 15 (23.0%)     | 0.62    |
| Posterior                          | 51 (85.0%) | 50 (79.0%)     | 0.85    |
| Barlows                            | 3 (2.4%)   | 3 (2.4%)       | 1.00    |
| Fail                               | 14 (23.3%) | 12 (19.2%)     | 0.44    |
| Myxomatous MV                      | 46 (60.0%) | 44 (68.0%)     | 0.72    |
| Restriction                        | 0 (0%)     | 0 (0%)         | 1.00    |
| Rheumatic                          | 1 (1.7%)   | 0 (0%)         | <0.001  |
| Post-op echo                       | 48 (80.0%) | 46 (79.0%)     | 0.72    |
| Post-op residual MR                | 28 (46.7%) | 26 (42.6%)     | 0.59    |
| MR severity post-op               |            |                |         |
| Mild or none                       | 26 (43.3%) | 24 (38.2%)     | 0.62    |
| Moderate                           | 5 (8.3%)   | 6 (9.6%)       | 1.00    |
| Severe                             | 1 (1.7%)   | 1 (1.6%)       | 1.00    |
| MAD post op echo                   | 2 (3.9%)   | 2 (3.2%)       | 0.34    |
| Follow up for post-op echo         | 834±790    | 660±693        | 0.24    |

**Table 3** Transthoracic echocardiographic data

| Variable                        | MAD (n=60) | No MAD (n=125) | p-value |
|---------------------------------|------------|----------------|---------|
| Post-operative events           |            |                |         |
| Follow up for mortality (years) | 4.1±2.3    | 3.9±2.2        | 0.59    |
| Atrial fibrillation             | 37 (61.7%) | 74 (59.2%)     | 0.87    |
| Atrial flutter                  | 4 (6.7%)   | 16 (12.8%)     | 0.31    |
| Non-sustained ventricular tachycardia | 0 (0%) | 3 (2.4%) | 0.55 |
| Ventricular tachycardia          | 0 (0%)     | 3 (2.4%)       | 0.55    |
| Ventricular fibrillation         | 0 (0%)     | 5 (4.0%)       | 0.52    |
| Stroke                          | 3 (5.0%)   | 10 (8.0%)      | 0.55    |
| Myocardial infarction            | 3 (5.0%)   | 6 (4.8%)       | 1.00    |
| Death                           | 28 (22.4%) | 12 (20.0%)     | 0.85    |

**Table 4** Long term arrhythmia and outcomes data
This evaluation provides insight into the echocardiographic characterization of MAD. In term of location, it is most commonly seen in the inferolateral left ventricular myocardial wall but it can be observed in nearly 1 in 4 patients in other left ventricular regions. In addition, MAD was more frequently seen in patients with myxomatous mitral valve disease and MVP particularly involving the P2 scallop as also reported by Lee et al. [6] There is also a greater proportion of patients with moderate or severe mitral regurgitation with MAD compared to no MAD. Compared to patients without MAD, patients with MAD have significantly higher left ventricular ejection fraction as previously seen in Essayagh et al. [10] and Konda et al. [11]

The mitral valve pathology and impact of surgery on MAD merits consideration. Among patients with degenerative mitral regurgitation with a flail leaflet, MV repair is associated with lower operative mortality, better long-term survival and is an independent predictor of higher postoperative ejection fraction. In addition, the conservation of the mitral valve architecture is associated with a more favourable geometry and remodelling of the left ventricle after surgical correction of the regurgitation. The current finding that most patients post mitral valve surgery who had MAD pre-surgery no longer had MAD on follow up echocardiogram may suggest that MAD is corrected by the techniques presented in the current study including annuloplasty only, annuloplasty and leaflet repair, resection with neo chords and valve replacement. More studies are needed to determine if indeed MAD may be corrected by stabilising the annulus only.

This study adds to the growing awareness of MAD as an incidental finding in patients and should be looked for in patients with MVP and myxomatous mitral valves. On TTE imaging, it can be seen in the parasternal long axis, apical four, two and three chamber views. The key to its identification is looking for it as it is only seen in ventricular systole. It is notable that it can be seen on other imaging modalities including transoesophageal echocardiography [7], cardiac magnetic resonance imaging [12] and computer tomography imaging [13]. As demonstrated in Mantegazza et al., it is likely that the improved spatial resolution of cardiac magnetic resonance and computed tomography imaging lead to higher MAD prevalence rates in comparison to TTE and transoesophageal echocardiography. [12]

The concern regarding ventricular arrhythmias with MAD has drawn recent interest. Van Wijngaarden et al. reported a higher frequency of ventricular arrhythmia in patients with MAD than without MAD in patients with MVP and moderate to severe mitral regurgitation (39% vs 20%, p ≤ 0.001) [14]. Similarly, the recent study by Essayagh et al. of 595 patients with isolated mitral valve prolapse found that after propensity score matching the patients with MAD are at increased risk of clinical arrhythmic events (HR 2.60 95%CI 1.87–3.62) but MAD was not linked to increased death within the first 10 years post-diagnosis [15]. Contrary to the findings of the current study was the finding that the link between MAD and arrhythmic events persisted with time-dependent surgery and was weaker after mitral surgery. The arrhythmia mechanism underlying MAD is largely unknown. It has been suggested that arrhythmias may be related to hypermobility of the associated MAD basal left ventricular region contributing to excessive mechanical stress on the mitral valve annulus resulting in myocyte hypertrophy, fibrosis and subsequent electrical instability resulting in ventricular arrhythmias [16]. In this study we found that patients with MAD had no increased risk of arrhythmias when compared to patient without MAD in a cohort of patients undergoing mitral valve surgery. This finding is consistent with the low rates of arrhythmic events and sudden death (3.8%) over a median of 20.3 years follow up that was reported by Konda et al [11] and the lack of increased risk of arrhythmias in patients with MAD who undergo transcatheter aortic valve replacement as described by Tsianaxa et al. [17] We build on the literature with the novel finding that current mitral valve surgical techniques are able to correct the MAD and there is no increase in developing residual mitral regurgitation which requires re-intervention among patients with MAD.

A key consideration is what to do with patients with MAD when it is found. Our evaluation found that no changes need to take place in terms of surgical approach for patients with and without MAD. In terms of post-surgical outcomes, there has been a growth of recent literature regarding the association between MAD and ventricular arrhythmias. There is evidence to support the use of implantable cardioverter defibrillators (ICD) following these arrhythmic events as secondary prevention. In the current study many patients did not have ventricular arrhythmias even at follow up. This suggests there is insufficient evidence for primary preventative use of ICD devices. It is likely that only a proportion of patients with MAD have increased arrhythmic risk and it has been suggested that those with MAD length > 8.5 mm are at high risk [18]. However, in our cohort many patients (average MAD length: 8.4 ± 3.9 mm) there were very few arrhythmic events in the group with MAD. More studies are needed to determine if there is a certain subgroup of patients who are more likely to have ventricular arrhythmias and what should be done to manage these patients.

Our evaluation has several limitations. First, data collection was retrospective and observational which may have inherent biases. However, the data is from a real
world setting making it generalizable to a population of patients requiring mitral valve surgery regardless of aetiology. Secondly, we acknowledge that a proportion of patients may have initially been from a different catchment area, or may have relocated to a different catchment area, which may have affected follow-up data collection. Thirdly, our study found an unexpected result that the proportion of patients with Barlow’s valve was low. This may be related to a diagnostic issue rather than a true finding as the data was retrieved from our local cardio-thoracic database and we were unable to ascertain how reliable the data is. Fourthly, our database of mitral valve surgery includes some patients that would have had the mitral valve disease as the primary problem while others may have coronary artery bypass grafting as their primary problem and mitral valve disease as a secondary problem. An important limitation is that the primary reason for surgery is not clear in our evaluation but it only affects a small portion of the cohort as only 19.5% had coronary artery bypass grafting. Finally, the mortality and ventricular arrhythmia data in the cohort may be more opportunistic based on our hospital records rather than systematic where the patients were contacted for follow-up.

Conclusion
MAD is common in patients who undergo mitral valve surgery. Current surgical techniques are able to correct the MAD abnormality in the vast majority of patients. MAD does not appear to be associated with an increased risk of adverse clinical outcomes after mitral valve surgery.

Abbreviations
ICD: Implantable cardioverter defibrillator; MACE: Major adverse cardiovascular events; MAD: Mitral annular disjunction; MVP: Mitral valve prolapse; TTE: Transthoracic echocardiography.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s44156-022-00004-7.

Additional file 1: Table S1. Comparison of the characteristics of the included vs excluded patients. Table S2. Additional mitral valve operation data. Table S3. Mitral valve operative data for patients with mitral valve prolapse or myxomatous mitral valve only. Table S4. Causes of death at follow up. Figure S1. Survival analysis of patients with and without MAD.

Acknowledgements
None.

Author contributions
CSK, PR, PN proposed the initial concepts of the project. SB and JT collated echocardiographic data, MB and CB collated patient demographic and clinical outcome data. CSK and SB wrote the main manuscript. All authors read, edited and agreed the final manuscript.

Funding
No funding was received for this guideline.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
The clinical audit was registered and approved by the host centre.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Heart and Lung Centre, University Hospitals of North Midlands, Stoke-on-Trent ST4 6QG, UK. 2 Keele University, Stoke-on-Trent, UK.

Received: 18 December 2021 Accepted: 24 May 2022
Published online: 13 July 2022

References
1. Hutchins GM, Moore GW, Skoog DK. The association of floppy mitral valve with disjunction of the mitral annulus fibrosus. N Engl J Med. 1986;314(9):535–40. https://doi.org/10.1056/NEJM198602273140902.
2. Donal E, Galli E, Letourneau T. The need for expertise in mitral valve regurgitation. Open Heart. 2019;6: e001039. https://doi.org/10.1136/openhrt-2019-001039.
3. David TE, Omran A, Armstrong S, et al. Long term results of mitral valve repair for myxomatous disease with and without chordal replacement with expanded polytetrafluoroethylene sutures. J Thorac Cardiovasc Surg. 1998;115(6):1279–85. https://doi.org/10.1016/S0022-5223(98)70210-7.
1136/bmj.39333.541782.AD.
4. Schnittman SR, Itagaki S, Toyoda N, et al. Survival and long-term outcomes after mitral valve replacement in patients aged 18 to 50 years. J Thorac and Cardiovasc Surg. 2018;155:96–102. https://doi.org/10.1016/j. jcts.2017.08.018.
5. Hiemstra YL, Tomsic A, Gripari P, et al. Evolution from mitral annular dysfunction to severe mitral regurgitation in Barlow’s disease. Interact Cardiovasc Thorac Surg. 2021;52(4):306–14. https://doi.org/10.1093/icvts/ivaa304.
6. Lee AP-W, Jin C-N, Fan Y, et al. Functional implication of mitral annular disjunction in mitral valve prolapse: a quantitative dynamic 3D Echocardiographic Study. JACC Cardiovascular Imaging. 2017;10(12):1424–33. https:// doi.org/10.1016/j.jcmg.2016.11.022.
7. Eriksson MJ, Bitkover CY, Omran AS, et al. Mitral annular disjunction in advanced myxomatous mitral valve disease: echocardiographic detection and surgical correction. J Am Soc Echocardiogr. 2005;18(10):1014–22. https://doi.org/10.1016/j.echo.2005.06.013.
8. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. BMJ. 2007;335:806. https://doi.org/10.1136/bmj.39333.541782.AD.
9. Robinson S, Rana B, Oxborough D, et al. A practical guideline for performing a comprehensive transthoracic echocardiogram in adults. The British Society of Echocardiography minimum dataset. Echo Res Pract. 2020;7(4):GS9–93. https://doi.org/10.1530/ERP-20-0026.
10. Essayagh B, Laczuio L, Civaia F, et al. Usefulness of 3-Tesla cardiac magnetic resonance to detect mitral annular dysfunction in patients with mitral valve prolapse. Am J Cardiol. 2019;124(11):1725–30. https://doi. org/10.1016/j.amjcard.2019.08.047.
11. Konda T, Tani T, Suganuma N, et al. Mitral annular disjunction in patients with primary severe mitral regurgitation and mitral valve prolapse.
Echocardiography. 2020;37(11):1716–22. https://doi.org/10.1111/echo.14896.

12. Mantegazza V, Volpato V, Gripari P, et al. Multimodality imaging assessment of mitral annular disjunction in mitral valve prolapse. Heart. 2020;107(1):25–32. https://doi.org/10.1136/heartjnl-2020-317330.

13. Toh H, Mori S, Iiawa Y, Fujita H, Miwa K, et al. Prevalence and extent of mitral annular disjunction in structurally normal hearts: comprehensive 3D analysis using cardiac computed tomography. Eur Heart J Cardiovasc Imaging. 2021;22(6):614–22. https://doi.org/10.1093/ehjci/jeab022.

14. Van Wijngaarden AL, De Riva M, Hijmistra YL, et al. Parameters associated with ventricular arrhythmias in mitral valve prolapse with significant regurgitation. Heart. 2020;107(5):411–8. https://doi.org/10.1136/heartjnl-2020-317451.

15. Essayagh B, Sabbag A, Antoine C, et al. The mitral annular disjunction of mitral valve prolapse. Presentation and outcomes. JACC Cardiovasc Imaging. 2021;14(11):2073–87. https://doi.org/10.1016/j.jcmg.2021.04.029.

16. Syed FF, Ackerman MJ, McLeod CJ, et al. Sites of successful ventricular fibrillation ablation in bileaflet mitral valve prolapse syndrome. Circ Arrhythm Electrophysiol. 2016;9(5):e004005. https://doi.org/10.1161/CIRCEP.116.004005.

17. Tsianaka T, Matzaris I, Kobe A, et al. Mitral annular disjunction in patients with severe aortic stenosis: extent and reproducibility of measurements with computed tomography. Eur J Radio Open. 2021;8:100335. https://doi.org/10.1016/j.ejro.2021.100335.

18. Carmo P, Andrade MJ, Aguiar C, et al. Mitral annular disjunction in myxomatous mitral valve disease: a relevant abnormality recognizable by transthoracic echocardiography. Cardiovasc Ultrasound. 2010;8:53–9. https://doi.org/10.1186/1476-7120-8-53.